Details About Generic Salt ::  Haloperi

Main Medicine Class:: Antipsychotic,Butyrophenone   

(HAL-oh-pehr-i-dahl)
Haldol,  Apo-Haloperidol, Novo-Peridol, Peridol, PMS-Haloperidol, PMS-Haloperidol LA, Apo-Haloperidol, Novo-Peridol, Peridol, PMS-Haloperidol, PMS-Haloperidol LA
Haloperidol Decanoate
Haldol Decanoate 50, Haldol Decanoate 100,  Haldol LA, Rho-Haloperidol Decanoate, Haldol Decanoate 100,  Haldol LA, Rho-Haloperidol Decanoate
Class: Antipsychotic/Butyrophenone

 

Drugs Class ::

 Action Has antipsychotic effect, apparently due to dopamine-receptor blockage in CNS.

Indications for Drugs ::

 Indications Management of psychotic disorders; control of Tourette’s disorder in children and adults; management of severe behavioral problems in children; short-term treatment of hyperactive children. Long-term antipsychotic therapy (haloperidol decanoate). Unlabeled use (s): Treatment of phencyclidine (PCP) psychosis; antiemetic.

Drug Dose ::

 Route/Dosage

Individualize dosage. ADULTS: PO 0.5 to 40 mg/day in divided doses; up to 100 mg/day in severe cases. ADULTS: IM 0.5 to 5 mg q 60 min; however, q 4 to 8 hr may be satisfactory.

HALOPERIDOL DECANOATE

ADULTS: IM (deep injection) Initial dose is 10 to 20 times oral dose. Usually given q 4 wk. CHILDREN 3 to 12 YR: PO Initially 0.5 mg/day. Increase in 0.5 mg increments every 5 to 7 days until therapeutic effect is achieved. Total dose divided and given bid or tid.

Contraindication ::

 Contraindications Severe toxic CNS depression or comatose states from any cause; Parkinson’s disease.

Drug Precautions ::

 Precautions

Pregnancy: Haloperidol: Safety not established. Haloperidol decanoate: Category C. Lactation: Excreted in breast milk. Children: Do not use in children < 3 yr. IM form not recommended in children. Elderly or debilitated patients: More susceptible to effects; consider lower dose. Special risk patients: Use drug with caution in patients with cardiovascular disease or mitral insufficiency, history of glaucoma, EEG abnormalities or seizure disorders, prior brain damage, or hepatic or renal impairment. Antiemetic effects: Due to suppression of cough reflex, aspiration of vomitus possible. CNS effects: May impair mental or physical abilities, especially during first few days of therapy. Hepatic effects: Jaundice usually occurs in 2 to 4 wks of treatment and is considered a hypersensitivity reaction. Usually reversible. Neuroleptic malignant syndrome (NMS): Has occurred and is potentially fatal. Signs and symptoms are hyperpyrexia, muscle rigidity, altered mental status, irregular pulse, irregular BP, tachycardia, and diaphoresis. Sensitivity to neuroleptic drugs: May require lower dosage. Sudden death: Has been reported; predisposing factors may be seizures or previous brain damage. Flareup of psychotic behavior may precede death. Tardive dyskinesia: Syndrome of potentially irreversible, involuntary dyskinetic movements may develop. Prevalence is highest in elderly, especially women. Use smallest effective dose for shortest period of time needed. Tartrazine sensitivity: Note that tartrazine is a component of this product.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Orthostatic hypotension; hypertension; tachycardia; ECG changes. CNS: Tardive dyskinesia; tardive dystonia; insomnia; restlessness; anxiety; euphoria; agitation; drowsiness; depression; lethargy; headache; confusion; vertigo; seizures; exacerbation of psychotic symptoms; pseudoparkinsonism (eg, mask-like face, drooling, pill rolling, shuffling gait, inertia, tremors, cogwheel rigidity); muscle spasms; dyskinesia; akathisia; oculogyric crises; opisthotonos; hyperreflexia. DERM: Maculopapular and acneiform skin reactions; photosensitivity; hair loss. EENT: Cataracts; retinopathy; visual disturbances; mydriasis; increased IOP; nasal congestion. GI: Dyspepsia; anorexia; diarrhea; hypersalivation; nausea; vomiting; dry mouth. GU: Impotence; sexual dysfunction; priapism; urinary hesitancy or retention. HEMA: Agranulocytosis; leukopenia; leukocytosis; anemia. HEPA: Jaundice; impaired liver function. RESP: Laryngospasm; bronchospasm; increased depth of respiration. OTHER: Menstrual irregularities; breast enlargement; lactation; gynecomastia; hyperglycemia; hypoglycemia; hyponatremia; elevated prolactin levels; adynamic ileus (may lead to death).

Drug Mode of Action ::  

 Action Has antipsychotic effect, apparently due to dopamine-receptor blockage in CNS.

Drug Interactions ::

 Interactions

Anesthetics, opiates, alcohol: May increase CNS depressant effects. Anticholinergics: May increase anticholinergic effects. May worsen schizophrenic symptoms, decrease haloperidol serum concentrations, and lead to tardive dyskinesia. Carbamazepine: May decrease effects of haloperidol. Lithium: May induce disorientation, unconsciousness, and extrapyramidal symptoms.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Observe patient for extrapyramidal symptoms and tardive dyskinesia. Notify health care provider if symptoms develop.
  • Assess patient’s mental status throughout therapy.
  • Evaluate CBC and liver function studies before and periodically throughout therapy.
  • Assess I & O and bowel function frequently.
  • Observe safety precautions such as close patient supervision and removal of harmful objects from patient’s environment.
  • Increase bulk and fluids in patient’s diet to minimize constipation.
  • Keep the patient recumbent after IM injection to reduce hypotension.

OVERDOSAGE: SIGNS & SYMPTOMS
  CNS depression, somnolence, hypotension, extrapyramidal symptoms, hypertension, agitation, restlessness, convulsions, fever, hypothermia, hyperthermia, coma, autonomic reactions, ECG changes, cardiac arrhythmias

Drug Storage/Management ::

 Administration/Storage

  • Dilute liquid in fruit juice.
  • Observe patient carefully when administering to ensure medication is taken and not hoarded.
  • Give with food or full glass of water to minimize GI irritation.
  • Replace injectable form by oral form as soon as possible.
  • Protect liquid concentrate from light and store in opaque bottle.

Drug Notes ::

 Patient/Family Education

  • Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
  • Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
  • Instruct patient to use mouth rinses, good oral hygiene, and sugarless gum or candy to relieve dry mouth.
  • Advise patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to report these symptoms to health care provider: Drooling, tremors, shuffling gait, restlessness, muscle spasms, aching or numbness, weakness, impaired vision, sore throat, fever, bleeding or bruising, rash, or jaundice.
  • Inform patient of possible hair loss.
  • Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.